The international surgical journal with global reach

West German Study Plan B Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol 2019; 37: 799-808

Published: 29th April 2020

Authors: Nitz M, Gluz O, Clemens M, Malter W, Reimer T, Nuding B et al.

Conclusion

Five-year outcomes were similar in both treatments arms of this study that included 2449 women.

Pubmed Link